Guardian Pharmacy Services, Inc.
- Open
- 41.68
- Day high
- 42.06
- Day low
- 40.58
- Prev close
- 41.87
- Volume
- 173K
- Mkt cap
- $2.6B
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.85
- P/B
- 12.0
- P/S
- 1.8
- Yield
- —
- Per share
- —
Guardian Pharmacy Services, Inc. (GRDN) is a Healthcare company listed on NYSE. The stock is up 96% over the past year.
Guardian Pharmacy Services, Inc. (GRDN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GRDN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.24 | $0.29 | +20.8% | $337M | +2.0% |
| Mar 11, 2026 | $0.27 | $0.37 | +38.3% | $398M | +18.5% |
| Mar 26, 2025 | $0.21 | $0.24 | +14.3% | $339M | +4.8% |
| Sep 26, 2024 | — | $0.17 | — | $300M | — |
| Dec 31, 2023 | — | $0.10 | — | $1.0B | — |
| Sep 30, 2023 | — | $-0.19 | — | $263M | — |
| Jun 30, 2023 | — | $0.35 | — | $253M | — |
| Jun 30, 2022 | — | $-0.10 | — | $224M | — |
| Mar 31, 2022 | — | $0.30 | — | $211M | — |
| Dec 31, 2021 | — | $0.07 | — | $792M | — |
| Sep 30, 2021 | — | $0.20 | — | $204M | — |
| Sep 30, 2020 | — | $-0.05 | — | $182M | — |
GRDN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 7, 2026 | COSLER STEVEN Ddirector | Grant | 4,028 | — |
| May 7, 2026 | LEWIS RANDALL Jdirector | Grant | 4,028 | — |
| May 7, 2026 | Patchett Mary Suedirector | Grant | 4,028 | — |
| Mar 31, 2026 | Pharmacy Investors, LLCother: Member of 10% owner group | Option | 1,413,939 | — |
| Mar 31, 2026 | Cardinal Equity Fund, L.P.other: Member of 10% owner group | Option | 471,057 | — |
| Mar 31, 2026 | Forbes Kendallofficer: See Remarks | Option | 608,570 | — |
| Mar 31, 2026 | BINDLEY WILLIAM Edirector, 10 percent owner: | Option | 6,100,175 | — |
| Mar 31, 2026 | Burke Freddirector, officer: See Remarks | Option | 1,298,826 | — |
| Mar 31, 2026 | Salentine Thomas J Jrdirector, 10 percent owner: | Option | 6,100,175 | — |
| Mar 31, 2026 | Ackerman Johndirector | Option | 471,057 | — |
| Mar 31, 2026 | Ackerman Johndirector | Option | 1,413,939 | — |
| Mar 31, 2026 | Bindley Capital Partners I, LLC10 percent owner | Option | 6,100,175 | — |
| Mar 31, 2026 | Morris David Kdirector, officer: See Remarks | Option | 641,869 | — |
| Mar 24, 2026 | Morris David Kdirector, officer: See Remarks | Sell | 187,855 | $29.68 |
| Mar 24, 2026 | Cardinal Equity Fund, L.P.other: Member of 10% owner group | Sell | 275,728 | $29.68 |
Source: GRDN SEC Form 4 filings, latest May 7, 2026. For informational purposes only — not investment advice.
See the full GRDN insider & 13F page →Guardian Pharmacy Services, Inc. company profile
Overview
Guardian Pharmacy Services, Inc. (NASDAQ:GRDN) is a specialized pharmacy service company founded in 2003 and headquartered in Atlanta, Georgia. The company went public in April 2016 and has established itself as a focused provider of pharmacy services specifically designed for residents of long-term care facilities across the United States. Guardian operates in the intersection of healthcare and technology, serving lower-acuity care environments such as assisted living facilities, behavioral health facilities, and group homes through its suite of technology-enabled pharmacy solutions.
Business
Guardian Pharmacy Services operates in the specialized segment of pharmaceutical distribution and services tailored specifically for long-term care facilities (LTCFs). The company's core business revolves around providing comprehensive pharmacy services to residents in lower-acuity healthcare settings, which are facilities that provide care for individuals who need assistance with daily activities but do not require intensive medical intervention like hospitals or skilled nursing facilities. The company's primary offering centers around individualized clinical services, drug dispensing, and medication administration capabilities. This means Guardian handles the entire medication management process for LTCF residents, from clinical consultation and prescription fulfillment to ensuring proper medication administration protocols are followed. The long-term care pharmacy industry is highly specialized because it requires understanding complex regulatory requirements, managing multiple chronic conditions common in elderly populations, and coordinating with various healthcare providers. Guardian's technology platform includes Guardian Compass, which features data-driven dashboards that help local pharmacies plan, track, and optimize their business operations. The system uses data from Guardian's proprietary data warehouse to provide insights and analytics. Additionally, the company offers GuardianShield Programs specifically designed for LTCFs, which appear to focus on risk management and compliance support for these facilities. The company operates as a single business segment focused entirely on long-term care pharmacy services, generating revenue primarily through pharmacy services contracts with assisted living facilities, behavioral health facilities, and group homes across the United States.
Revenue model
Guardian generates revenue primarily through service contracts and pharmacy dispensing fees from long-term care facilities. The company's customers are the facilities themselves - assisted living centers, behavioral health facilities, and group homes - rather than individual residents. These facilities contract with Guardian to provide comprehensive pharmacy services for their residents, creating a B2B business model where Guardian serves as the pharmacy services provider. The revenue model is built on several components: prescription dispensing fees, clinical consulting services, technology platform subscriptions, and potentially medication management services. Given the company's 2024 revenue of approximately $1.23 billion, this represents a substantial operation serving numerous facilities across multiple states. Several factors can significantly impact Guardian's margins and profitability. Regulatory changes in healthcare reimbursement, particularly Medicare and Medicaid policies, directly affect the company's revenue since many LTCF residents rely on government-funded healthcare programs. Drug pricing fluctuations from pharmaceutical manufacturers can squeeze margins if Guardian cannot pass these costs through to customers. Labor costs, particularly for pharmacists and clinical staff, represent a significant expense that can pressure margins during tight labor markets. Competition from larger pharmacy chains and specialized competitors could pressure pricing and market share. Additionally, consolidation in the long-term care industry could create larger, more powerful customers with greater negotiating leverage. Conversely, the aging U.S. population and increasing demand for long-term care services could drive volume growth and support margin expansion through economies of scale.
Competitive moat
Guardian's competitive moat appears moderately strong but not insurmountable. The company benefits from several defensive characteristics inherent to the long-term care pharmacy sector. First, there are significant regulatory barriers and compliance requirements that create hurdles for new entrants, as serving LTCF populations requires specialized knowledge of Medicare/Medicaid regulations, state pharmacy laws, and long-term care facility requirements. The company's technology platform and data analytics capabilities provide some differentiation, particularly the Guardian Compass system that helps facilities optimize operations. However, technology advantages in this sector can be replicated over time by well-funded competitors. Switching costs for long-term care facilities provide some protection, as changing pharmacy service providers involves operational disruption, staff retraining, and potential compliance risks that facilities prefer to avoid. The company's established relationships and local market presence create some customer stickiness, as long-term care facilities value reliable, consistent service delivery. However, Guardian faces meaningful competitive threats from larger pharmacy chains like CVS Health and Walgreens, which have significantly more resources and could expand aggressively into this market. Regional competitors with strong local relationships also pose ongoing competitive pressure. The moat is further challenged by the fact that the core service - pharmacy dispensing and clinical consultation - is not proprietary and can be replicated by competitors with sufficient investment in technology and regulatory compliance infrastructure. While Guardian has built a solid position in its niche, the competitive advantages are more operational than structural.
Risks & safety
Guardian's margin of safety appears concerning based on recent financial performance and current valuation metrics. • Cash and liquidity concerns: Cash position dropped dramatically from $37.2 million in Q3 2024 to just $4.7 million by Q4 2024, indicating potential cash flow stress • Debt levels: Debt-to-equity ratio increased to 0.21 by Q4 2024, though still manageable • Profitability volatility: Company swung from $37.7 million net income in 2023 to -$71.0 million loss in 2024, with a particularly severe Q3 2024 loss of -$105.8 million • Valuation metrics: Trading at 34.9x P/E ratio based on Q1 2025 earnings, which appears expensive given the earnings volatility • Current ratio: Improved to 1.14 in Q1 2025 but remains relatively tight for working capital needs • Free cash flow: Generated positive $11.7 million in Q1 2025, but 2024 full-year performance was mixed with significant quarterly variations • EV/EBITDA: Currently 25.2x, which is elevated for a service company with operational challenges The dramatic earnings volatility and low cash position suggest limited financial cushion to weather operational difficulties or economic downturns.
Recent development
Based on the available financial data, Guardian appears to have experienced significant operational challenges in 2024, particularly during the third quarter when the company reported a substantial loss of $105.8 million. This dramatic swing from profitability in 2023 (when the company earned $37.7 million) to losses in 2024 suggests the company underwent major operational disruptions or strategic changes. The company's revenue growth trajectory shows expansion from $908.9 million in 2022 to $1.05 billion in 2023, and further to $1.23 billion in 2024, indicating continued market expansion despite profitability challenges. However, the significant losses in 2024 suggest that this growth may have come at the expense of operational efficiency or involved substantial one-time costs. The recovery shown in Q4 2024 and Q1 2025, where the company returned to profitability with $11.9 million and $9.3 million in net income respectively, indicates that Guardian may have successfully addressed whatever operational issues caused the Q3 2024 losses. The improvement in cash flow from operations, which reached $17.6 million in Q1 2025, suggests operational stabilization. Without access to detailed earnings call transcripts, the specific nature of Guardian's strategic initiatives, new product launches, or operational changes during this period remains unclear, but the financial pattern suggests a significant operational restructuring or integration challenge that has been largely resolved by early 2025.
GRDN company profile · for informational purposes only — not investment advice.
Track GRDN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free